During ordinary non-dream sleep, people who are awakened report only vague and sketchy thoughts, and their experiences do not cohere into a continuous narrative. During dream sleep, in contrast, people who are awakened report rich and detailed experiences in which events form a continuous progression, which may however be interrupted by bizarre or fantastic intrusions. Thought processes during the dream state frequently show a high level of irrationality. Both dream and non-dream states are associated with severe disruption of memory: it usually disappears in seconds during the non-dream state, and in minutes after awakening from a dream unless actively refreshed.Research conducted on the effects of partial epileptic seizures on consciousness found that patients who have partial epileptic seizures experience altered states of consciousness. In partial epileptic seizures, consciousness is impaired or lost while some aspects of consciousness, often automated behaviors, remain intact. Studies found that when measuring the qualitative features during partial epileptic seizures, patients exhibited an increase in arousal and became absorbed in the experience of the seizure, followed by difficulty in focusing and shifting attention. A variety of psychoactive drugs, including alcohol, have notable effects on consciousness. These range from a simple dulling of awareness produced by sedatives, to increases in the intensity of sensory qualities produced by stimulants, cannabis, empathogens–entactogens such as MDMA ("Ecstasy"), or most notably by the class of drugs known as psychedelics.
Adverse effects
During controlled clinical studies with the recommended dosage, the incidence of adverse effects was comparable to that of placebo, with the exception of insomnia and dry mouth, both of which were commonly reported. Contraindications
Clarinase is contraindicated in patients receiving MAO inhibitor therapy or within 14 days of discontinuing such treatment and in patients with narrow angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease and hyperthyroidism. References
Drugs.com: Claritin-D
Israel Ministry of Health: Clarinase Repetabs
Haberfeld H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. Clarinase 5 mg/120 mg Retardtabletten. ISBN 978-3-85200-196-8.